The Medical Letter on Drugs and Therapeutics
Insulin Glargine (Lantus) and Cancer Risk
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Several large European observational studies published on-line this summer have raised questions about whether use of insulin glargine increases the risk of cancer.

GLARGINE — Insulin glargine (Lantus – Sanofi Aventis) is one of 3 basal insulins marketed in the US. Insulin detemir (Levemir) and NPH (Humulin N; Novolin N) are the others. Insulin glargine is a recombinant DNA analog of human insulin; it forms microprecipitates in subcutaneous tissue, delaying absorption and prolonging its duration of action to 22 ± 4 hours, which makes it the longest-acting basal insulin.1

DIABETES AND CANCER — Type 2 diabetes has been associated with an increased risk of breast cancer (20%), colon cancer (30%) and pancreatic cancer (50%); type 1 diabetes has not been associated with an increase in the incidence of these tumors. Type 2 diabetes is also associated ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Insulin Glargine (Lantus) and Cancer Risk
Article code: 1319c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian